Ropinirole and pramipexole, the new agonists

Canadian Journal of Neurological Sciences

Volumn 26, Issue SUPPL. 2, 1999, Pages

  Hobson, Douglas E ^a   Pourcher, Emmanuelle ^b   Martin, W R Wayne ^c,d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d GLENROSE REHABILITATION HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOMPERIDONE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; COMBINATION CHEMOTHERAPY; DOSE CALCULATION; DRUG COST; DRUG DISPOSITION; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MOTOR DYSFUNCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY; TREATMENT OUTCOME;

EID: 0032797124     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100000068     Document Type: Article

References (53)

1. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-hydroxytyramin) im Gerhirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyraminalen Systems. Klin Wschr. 1960; 38: 1236.
2. Barbeau A, Sourkes TL, Murphy GR: Les catecholamines dans la maladie de Parkinson. In: De Ajuriaguerra J (ed): Monoamines et Systeme Nerveux Central. Paris: Masson: 1962: 247-262.
3. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of Parkinsonism. N Engl J Med 1967; 276: 374-379.
4. Uitti RJ, Ahlskog JE, Maragamore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmstead County Project. Neurology 1993; 43: 1918-1926.
5. Fahn S. Adverse effects of levodopa in Parkinson's Disease. In: Calne DB, ed. Drugs for the Treatment of Parkinson's Disease (Handbook of Experimental Pharmacology). Berlin, Heidelberg: Springer Verlag 1989; 88: 443-438.
6. Juncos JL, Engber TM, Raisman R, et al. Continuous and intermittant levodopa differentially affect basal ganglia function. Ann Neurol 1989; 25: 473-478.
7. Nutt JG. Levodopa-induced dyskinesia. Neurology 1990; 40: 340-345.
8. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990; 40 (Suppl 3): 32-37.
9. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32: 804-812.
10. Micel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990; 26: 428-435.
11. Mena MA, Pardo B, Casarejos MJ, Fahn S, Garcia de Yebenes J. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992; 7: 23-31.
12. Agid Y. Levodopa: is toxicity a myth? Neurology 1998; 50: 858-863.
13. Olanow CW. Single-blind double crossover-controlled study of carbidopa/levodopa vs. BCT in untreated Parkinson patients. Arch Neurol 1988; 45: 206.
14. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995; 45(Suppl3): S13-S21.
15. Quinn N. Drug treatment of Parkinson's disease. Br Med J 1995; 310: 575-579.
16. Eisle T, Hall RP, Kalavar KA, et al. Erythromelalgia-like eruption in Parkinsonian patients treated with bromocriptine. Neurology 1982; 32: 577-583.
17. Todman DH, Oliver WA, Edward R.L. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. Clin Exp Neurol 1990; 27: 79-82.
18. Jimenez-Jiminez FJ, Lopez-Alvarez J, Sanchez-Chapado M, et al. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol 1995; 18: 277-279.
19. Eden RJ, Costall B, Domeney AM, et al. Preclinical pharmacology of ropinirole (SKF101468-A), a novel dopamine D2 agonist. Pharmacol Biochem Behaviour 1991; 38: 147-154.
20. Bowen WP, Coldwell MC, Hicks FR, Riley GJ, Fears R. Ropinirole, a novel dopaminergic agent for the treatment of Parkinson's disease, with selectivity for cloned D2 receptors. Br J Pharmacol 1993; 110 (Suppl): 93p.
21. Tulloch I. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997; 49 (Suppl 1): S58-S62.
22. Sautel F, Griffon N, Levesque D, et al. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport 1995; 6: 329-332.
23. Mierau J, Schingnitz G. Biochemical and pharmacological studies on prampipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 1992; 215: 161-170.
24. Mierau J, Schneider FJ, Ennsinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2,D3, and D4 receptors. Eur J Pharmacol 1995; 29: 290.
25. Willner P, Lappas S, Cheeta S, et al. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacol 1994; 115: 454-462.
26. Gerfen CR. Dopamine function in the striatum: implications for dopamine receptor agonist treatment of Parkinson's disease. In: Olanow CW, Obeso JA, eds. Beyond the Decade of the Brain: Dopamine Agonists in Early Parkinson's Disease 1997; 2: 55-74.
27. Boothman BR, Spokes EG, Pharmacokinetic data for ropinirole. Lancet 1990; 336: 814.
28. Brefel C. et al. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin Pharmacol. 1998; 45: 412-415.
29. Bloomer JC, Clark SE, Cherney RJ. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos 1997; 25: 840-844.
30. Schilling C, Haselbarth V. SND 919 increasing dose or study in health volunteers after oral administration. Boehringer Ingelheim, Germany (unpublished report U89-0039/836.001), Nov. 1988.
31. Haselbarth V, et. al. SND 919 CL 2 Y: Pharmocokinetics and bioavailability of SND 919 CL 2Y, comparison of the plasma levels after intravenous (infusion 100 mcg), oral (tablets, 300 mcg) and oral (solution, 300 mcg) administration in 12 healthy volunteers (3-fold cross-over). Germany (unpublished report U91-0026/836.005), Sept 28, 1990.
32. Kiorpes AL. Two-week oral drug interaction study with SND 919, Eldepryl and Sinemet in rhesus monkeys. Internal report, Boehringer Ingelheim, U91-022, 1990.
33. Bedard PJ, Gomez-Mancilla B, Blanchet P, et al. Dopamine agonists as a first line therapy of parkinsonism in MPTP monkeys. In: Olanow CW, Obeso JA, eds. Beyond the Decade of the Brain: Dopamine Agonists in Early Parkinson's Disease. 1997; 2: 101-110.
34. Rinne UK Dopamine agonists as primary treatment in Parkinson's disease. Adv Neurol 1986; 45: 519-523.
35. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997; 49(Suppl 1): S58-S62.
36. Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease. Neurology 1997; 49 (Suppl 1): S26-S33.
37. Pearce RKB, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998; 13: 234-241.
38. Brooks DJ, Turjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995; 45(Suppl): 231-238.
39. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB eds. Recent Developments in Parkinson's Disease. New York; Macmillan, 1987: 153-163.
40. Kreider MS, Wilson-Lynch K, Gardiner DE, Wheadon DE. A double blind, placebo controlled extension study to evaluate the 12-month efficacy and safety of ropinirole in early Parkinson's disese. Neurology 1997; 48 (Suppl 2): A269.
41. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's Disease. Neurology 1997; 49: 393-399.
42. Rascol O, Brooks D, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5 year levodopa-controlled study. Mov Disord 1998; 13: 39-45.
43. Korczyn M, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord 1998; 13: 46-51.
44. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18: 338-347.
45. Parkinson's Study Group. Safety and efficacy of pramipexole in early Parkinson's disease: a randomized dose ranging study. JAMA 1997; 278: 125-130.
46. Shannon KM, Bennett Jr, Freidman JH, et al. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997; 49: 724-728.
47. Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996; 19: 234-245.
48. Kreider M, Knox S, Gardiner D, et al. A multicenter double blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease. Neurology 1996; 46(Suppl 2): 475.
49. Ropinirole 043 study group. A double blind comparative study of ropinirole versus bromocriptine in the treatment of parkinsonian patients not optimally controlled on L-dopa. Mov Disord 1996; 11(Suppl 1): 188.
50. Mohlo ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advancd Parkinson's disease. J Neural Transm 1995; (S)45: 225-230.
51. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double blind, placebo controlled, parallel-group study. Neurology 1997; 49: 162-168.
52. Guttman M, and the International Pramipexole-Bromocriptine Study Group. Double blind comparison of bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997; 49: 1060-1065.
53. Hauser R, Zesiewicz T. Parkinson's Disease: Questions and Answers 2nd ed. (ed.). Merit Publishing International. 1997: 66.